source
- Lilly cans early experimental obesity drug after ‘high bar’ not metEli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.Fierce Biotech · 5h ago↗ source
- Analysis says secret Trump pharma deals could cut projected Medicare savings from MFN pricing by up to 80%A new analysis warns that confidential agreements between the Trump administration and more than two dozen drug makers could dramatically shrink the savings expected from the "most‑favored‑nation"…